Delivery Order SPE2DB24D3013-SPE2DB25FFNPA
- Not listed
- The Defense Logistics Agency awarded a $10,738.28 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Gemtesa 75 mg, with an ultimate completion date of July 22, 2025. This is a firm fixed price, non-set-aside contract executed on July 21, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency awarded a delivery order valued at $12,731.89 to AmerisourceBergen Drug Corp for 90-count tablets of Gemtesa 75 mg, a pharmaceutical product for treating overactive bladder. The contract, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a firm fixed-price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a...
- The Defense Logistics Agency awarded a $7,983.28 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 90 tablets of Gemtesa 75 mg, with an ultimate completion date of July 24, 2025. This non-set-aside competitive award was issued to AmerisourceBergen's Corporate Office, headquartered in Conshohocken, Pennsylvania, where the pharmaceutical products will be delivered. The contract represents a routine pharmaceutical procurement supporting federal medical supply requirements,...
- The Defense Logistics Agency has awarded a delivery order valued at $10,816.44 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units). This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by July 22, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order...
- The Defense Logistics Agency awarded a $57,659.25 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 90-count bottles of Gemtesa 75 mg tablets, with an ultimate completion date of July 25, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's broader supply relationship with the federal government. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Gemtesa 75 mg tablets (30-count packages) with a contract ceiling value of $4,316.81. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive procurement. The order is to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,522.97 to AmerisourceBergen Drug Corp for 90 tablets of Gemtesa 75 mg, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order, awarded on July 25, 2025, represents a non-set-aside competitive award for pharmaceutical supply to support federal medical procurement needs. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $12,290.03 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count supply) on July 23, 2025, with completion scheduled for July 24, 2025. This non-competitive delivery order utilizes firm fixed pricing and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, fulfills this...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 21, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $16,491.74. This firm fixed-price delivery order, which is due for completion by July 22, 2025, represents a pharmaceutical supply requirement under DLA's medical procurement operations. The award was competitively awarded with no set-aside designation, and AmerisourceBergen will perform the work at its...
- The Defense Logistics Agency awarded a delivery order valued at $8,344.44 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Gemtesa 75 mg tablets in quantities of 90 units. This competitive delivery order is structured as a firm fixed price contract with an ultimate completion date of July 22, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Gemtesa is a prescription medication used in the treatment of overactive bladder,...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFNPADelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,779.72 for 90 tablets of Gemtesa 75 mg on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was used for this award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal medical procurement vendor specializing in military and veteran healthcare supply. The DLA Troop Support Medical IDC enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products, medical supplies, vaccines, and specialty medications to support military healthcare programs globally. This delivery order for Gemtesa, a medication used in the treatment of overactive bladder, reflects the company's role in fulfilling ongoing medical commodity requirements across the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 7/22/25 |